Wockhardt: FDA booster
STOCK IN THE NEWS
| Earlier last week the company got approval for marketing Furosemide injection and approval of painkiller tablets containing a combination of Dextropropoxyphene napsylate and Acetaminophen in the US. |
| The stock appreciated more than 4 per cent after the announcement. In last one week, the stock moved from Rs 382.10 on March 23 to close at Rs 397.65 on Friday. Export income accounts for one-third of the total income of the company. |
| Ketorolac anti-inflammatory injection is the company's fifth injection product in the US. The product is a potent non-steroidal anti-inflammatory drug used in the management of acute pain following surgery and trauma. |
| Furosemide injection is one of the most widely used diuretics (drugs that promote excretion of urine) in hospitals and ICUs in several life-threatening conditions. |
| Over 40 million vials of Ketorolac injections, valued at $36 million, are consumed annually by hospitals across the US, as per IMS. The company currently markets 15 products in the US, with two more to be launched soon. |